A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A study for patients with advanced refractory solid tumors using study drug Varlilumab
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAO7762
U.S. Govt. ID: NCT02423343
Contact: Ryan Shelton: 212-304-5485 / rs3323@columbia.edu
Additional Study Information: The purpose of this research study is to test the effectiveness (how well the drug works), safety, and tolerability varlilumab and nivolumab (investigational drugs) together in patients with advanced solid tumors. Varlilumab and nivolumab are antibodies (types of human protein) that are manufactured in a laboratory and are being tested to see if they will allow the body's immune system to work against tumor cells. This is the first time varlilumab and nivolumab have been tested together in humans. Using similar agents in cancer models in mice showed that combining the treatments worked better than either treatment alone.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Do you have a history of cardiovascular disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton